Professor Bill Sessa Appointed Chair of Isomab’s Scientific Advisory Board

Former Chief Scientific Officer of Internal Medicine at Pfizer: Leading vascular biologists from Yale, Harvard, Uppsala and the University of Eastern Finland join Sessa to advise on the development of ISM-001, Isomab’s first-in-class anti-VEGF-A165b antibody for chronic angina